Candel Therapeutics, Inc. develops clinical-stage multimodal biological immunotherapies for cancer, including off-the-shelf viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Company news commonly covers aglatimagene besadenovec, also called aglatne or CAN-2409, in prostate cancer and non-small cell lung cancer, and linoserpaturev, or CAN-3110, from its HSV platform in recurrent high-grade glioma.
Updates also include clinical-data presentations, FDA designations or clearances, research-and-development communications, quarterly financial results, financing activity, and Nasdaq inducement grants under the company’s equity plans.
Candel Therapeutics (CADL) will present two accepted posters at the SITC Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.
The November 6 poster covers aglatimagene besadenovec in non-small cell lung cancer progressing despite immune checkpoint inhibitor treatment. The November 7 poster covers clinical and mechanistic findings from the phase 1b trial of linoserpaturev in recurrent glioblastoma.
Candel Therapeutics (CADL) granted stock options covering 85,900 common shares to four new employees on September 30, 2026.
The options have a $10.44 per-share exercise price and were granted under the company's 2025 Inducement Plan as employment inducements under Nasdaq Listing Rule 5635(c)(4). Each award vests 25% on the first anniversary of the employee's start date, with the remaining 75% vesting in 36 equal monthly installments thereafter. All vesting requires continued service through the applicable vesting date.
Candel Therapeutics (CADL) published final phase 2a results showing median overall survival of 24.5 months in evaluable patients with advanced lung cancer. The peer-reviewed study covered 46 evaluable patients with unresectable stage III/IV non-small cell lung cancer and inadequate response to immune checkpoint inhibitors. Patients received aglatimagene besadenovec plus valacyclovir with continued inhibitor therapy. Historical docetaxel survival benchmarks were 9.8–11.8 months, not a concurrent comparison.
Median survival was 21.5 months among 41 patients with disease progression at baseline and 25.4 months among their 33 non-squamous cases. Reduction of uninjected lesions occurred in 69% of 35 evaluable patients with multiple lesions. Grade 3 treatment-related adverse events occurred in 13.7%; no dose-limiting toxicities or unexpected safety signals were identified. The phase 3 AURORA trial is enrolling globally.
Candel Therapeutics (Nasdaq: CADL) reported systemic immune activation after aglatimagene besadenovec treatment in patients with intermediate-risk localized prostate cancer.
Early phase 2 PrTK05 blood analyses involved 13 patients receiving aglatimagene plus external beam radiation therapy and six receiving standard care alone. Cytotoxic T-cell populations expanded in the treatment arm; formal comparison with controls is ongoing. In the phase 3 PrTK03 intermediate-risk subgroup of 635 patients, treatment reduced prostate cancer recurrence or prostate cancer-specific death risk by 41% versus placebo plus radiation, with median follow-up of 58.0 months. Negative biopsies occurred in 76.6% versus 60.7% of evaluable patients, and exploratory tissue analyses showed immune changes more than two years after treatment. Candel plans a Q4 2026 FDA biologics license application, including compiled PrTK05 biodistribution and shedding data.
Candel Therapeutics (CADL) presented new phase 3 biomarker data showing sustained immune changes after aglatimagene besadenovec treatment in localized prostate cancer.
AI-enabled analysis covered 622 pre-treatment and 427 post-treatment biopsies, with post-treatment samples collected more than two years after radiation completion. Aglatimagene plus external beam radiation increased lymphocyte infiltration compared with placebo plus radiation. Paired biopsies from 108 patients with residual tumor also showed increased immune-cell infiltration and interaction with tumor cells. Previously reported negative-biopsy rates two years after treatment were 80% versus 63% for evaluable aglatimagene and control patients. Candel plans to submit a Biologics License Application.
Candel Therapeutics (CADL) has appointed Martine Zimmermann, PharmD, to its Board of Directors, effective September 8, 2026.
The company highlights her more than 30 years of global regulatory affairs and quality experience across all phases of drug development. Zimmermann currently serves as Executive Vice President, Head of Regulatory Affairs, Quality and Alliance Management at Inventiva S.A., and previously held senior regulatory roles at Ipsen Biopharmaceuticals and Alexion Pharma International. Candel is preparing a planned Biologics License Application submission for aglatimagene besadenovec in the fourth quarter of 2026 and describes this appointment as strengthening its path toward potential commercial readiness.
Candel Therapeutics (Nasdaq: CADL) reported that on August 31, 2026, its Board Compensation Committee granted inducement stock options to two new employees for an aggregate of 31,400 shares of common stock at an exercise price of $13.07 per share under the 2025 Inducement Plan.
According to Candel Therapeutics, the options vest 25% on the first anniversary of each employee’s start date, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service. The awards were approved as employment inducements in line with Nasdaq Listing Rule 5635(c)(4). The 2025 Inducement Plan was adopted by the Board on December 24, 2025.
Candel Therapeutics (Nasdaq: CADL) announced that President and CEO Paul Peter Tak will participate in analyst-led fireside discussions and one-on-one meetings at three New York investor conferences in September 2026: Citi's 2026 Biopharma Back to School Conference, Cantor Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference.
Sessions are scheduled for September 9, 10, and 15, 2026, with live webcasts and 90-day replays accessible via the Events & Presentations section of Candel’s investor website.
Candel Therapeutics (Nasdaq: CADL) reported second quarter 2026 results and clinical progress for its multimodal immunotherapy pipeline. The company plans to submit a Biologics License Application in Q4 2026 for aglatimagene besadenovec in localized intermediate- to high-risk prostate cancer, supported by pivotal phase 3 data in The Lancet Oncology.
Extended follow-up from the 745‑patient phase 3 trial showed a 39% improvement in prostate cancer‑specific disease‑free survival for the aglatimagene arm versus placebo after a 58‑month median follow‑up, with no new safety signals. Candel also activated the first site and opened enrollment for the global pivotal phase 3 AURORA trial in metastatic non‑squamous NSCLC and advanced IND‑enabled planning for a randomized phase 2 study of linoserpaturev in recurrent glioblastoma.
Candel appointed oncology veteran Mark Sims as Chief Commercial Officer and entered a commercialization agreement with EVERSANA to support a potential 2027 U.S. launch of aglatimagene. The company ended June 30, 2026 with $201.6 million in cash, expected to fund operations into Q1 2028, and reported a quarterly net loss of $38.9 million.
Candel Therapeutics (Nasdaq: CADL) reported that on July 31, 2026, its Board Compensation Committee granted inducement stock options to three new employees to purchase an aggregate of 30,800 shares of common stock at an exercise price of $10.01 per share.
According to Candel Therapeutics, the awards were granted under the 2025 Inducement Plan, adopted on December 24, 2025, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4). Vesting covers 25% of shares on the first employment anniversary and the remaining 75% in 36 equal monthly installments, subject to continued service.